Carl Sylvester, MD
Ophthalmology · Oklahoma City, OKNPI 1831241587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Alcon at 48.2% of the total. 2025 is the largest year on record at $766, 2.1 times the $367 reported in 2019.
Across 128 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$269
- Rxsight Inc$267
- Tarsus Pharmaceuticals, Inc.$232
- Bausch & Lomb Americas Inc.$179
- Sun Pharmaceutical Industries Inc.$115
- plus $610 from 17 others
Across 10 payments — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$40K
What the payments were for
- Food & beverage$3,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 49 | $1,555 |
| AbbVie(2 entities) | 16 | $269 |
| Rxsight Inc | 13 | $267 |
| Tarsus Pharmaceuticals, Inc. | 6 | $232 |
| Bausch & Lomb Americas Inc. | 5 | $179 |
| Sun Pharmaceutical Industries Inc. | 7 | $115 |
| Dompe US, Inc. | 5 | $106 |
| Glaukos Corporation | 4 | $92 |
| Oyster Point Pharma, Inc. | 3 | $77 |
| Shire North American Group Inc | 2 | $44 |
| Harrow Eye, LLC | 2 | $36 |
| Ocular Therapeutix, Inc. | 2 | $36 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $33 |
| Novartis | 2 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $25 |
| Omeros Corporation | 2 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Thea Pharma Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Amgen | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $9 |
| Optos, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$231
- ReSTOR$129
- XDEMVY$124
- Clareon PanOptix Pro$123
- ORA$118
- AcrySof IQ PanOptix$114
How this compares
$3,227 in reported general payments places this provider in the 80th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 14 | $386,813 |
| LumiganBimatoprost | 67 | $38,943 |
| RestasisCyclosporine | 21 | $30,589 |
| XiidraLifitegrast | 13 | $25,153 |
| Prednisolone Acetate | 362 | $10,440 |
| Brimonidine Tartrate | 39 | $7,427 |
| Ketorolac Tromethamine | 249 | $5,574 |
| MoxifloxacinMoxifloxacin Hcl | 182 | $5,203 |
| Travoprost | 17 | $4,582 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $4,384 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,379 |
| Latanoprost | 233 | $3,983 |
| Timolol Maleate | 180 | $2,073 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $1,610 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 85 | $910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $106 | $386,81314 claims |
| AbbVieLumigan, Restasis, Combigan | $269 | $73,91099 claims |
| Bausch & Lomb Americas Inc.Xiidra | $179 | $25,15313 claims |
| AlconSimbrinza | $1,555 | $4,38414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Oklahoma City
- Ronald RebenitschOklahoma City$141K
- Edward JonesOklahoma City$13K
- John BelardoOklahoma City$12K
- David KorberOklahoma City$11K
- Jason NguyenOklahoma City$9K
- Annie ChanOklahoma City$6K
- Lance ScottOklahoma City$5K
- Craig EckOklahoma City$5K
- Valerie LobodiakOklahoma City$4K
- Clifton FayOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.